Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. - Nemunaitis,J.; Khuri,F.; Ganly,I.; Arseneau,J.; Posner,M.; Vokes,E.; Kuhn,J.; McCarty,T.; Landes,S.; Blackburn,A.; Romel,L.; Randlev,B.; et al. (J Clin Oncol, 2001)